Polyrizon Ltd.
$1.03
-0.08 (-7.21%)
PLRZ Price Chart
| Basic | |
|---|---|
| Market Cap | $4.49M |
| Price | $1.03 |
| 52 Week Range | 0.77-4.8 |
| Beta | 0.00 |
| Margins | |
| Gross Profit Margin | 0.00% |
| Operating Profit Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Valuation (TTM) | |
| P/E Ratio | -2.90 |
| Price to Sales Ratio | 0.00 |
| Price to Book Ratio | 0.85 |
| PEG Ratio | 0.05 |
Industry
Biotechnology
Sector
Healthcare
Full-Time Employees
1
IPO Date
2024-10-29T00:00:00.000Z
Description
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Phone
972 9 374 0120
Address
5 Ha-Tidhar Street, Ra'anana, 4366507, IL
CIK
0001893645